CLLS vs. TSHA, VALN, EXAI, KYTX, CABA, LXEO, ADPT, ALEC, EDIT, and OCGN
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Taysha Gene Therapies (TSHA), Valneva (VALN), Exscientia (EXAI), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Lexeo Therapeutics (LXEO), Adaptive Biotechnologies (ADPT), Alector (ALEC), Editas Medicine (EDIT), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.
Cellectis (NASDAQ:CLLS) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
Cellectis presently has a consensus target price of $8.50, suggesting a potential upside of 213.65%. Taysha Gene Therapies has a consensus target price of $7.00, suggesting a potential upside of 104.08%. Given Cellectis' higher probable upside, equities analysts clearly believe Cellectis is more favorable than Taysha Gene Therapies.
Cellectis received 316 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 74.17% of users gave Taysha Gene Therapies an outperform vote while only 67.95% of users gave Cellectis an outperform vote.
In the previous week, Cellectis had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Cellectis and 9 mentions for Taysha Gene Therapies. Cellectis' average media sentiment score of 0.58 beat Taysha Gene Therapies' score of 0.41 indicating that Cellectis is being referred to more favorably in the media.
Cellectis has a beta of 3.08, meaning that its stock price is 208% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
Cellectis has a net margin of -529.81% compared to Taysha Gene Therapies' net margin of -833.60%. Cellectis' return on equity of -67.41% beat Taysha Gene Therapies' return on equity.
63.9% of Cellectis shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cellectis has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectis beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
